|
|
Volumn 24, Issue 6, 2007, Pages 1290-1304
|
|
Reducing cardiovascular risk by blockade of the renin-angiotensin- aldosterone system
|
|
Author keywords
Angiotensin receptor blocker; Angiotensin converting enzyme; Cardiovascular; Myocardial infarction; Renin angiotensin aldosterone system
|
|
Indexed keywords
ALISKIREN;
AMLODIPINE;
ANGIOTENSIN 2 RECEPTOR ANTAGONIST;
ANGIOTENSIN RECEPTOR ANTAGONIST;
ANTIHYPERTENSIVE AGENT;
ATENOLOL;
BENAZEPRIL;
BENDROFLUMETHIAZIDE;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
CANDESARTAN;
CAPTOPRIL;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
ENALAPRIL;
EPROSARTAN;
INOTROPIC AGENT;
IRBESARTAN;
LOSARTAN;
NITRENDIPINE;
PERINDOPRIL;
PLACEBO;
RAMIPRIL;
TELMISARTAN;
THIAZIDE DIURETIC AGENT;
TRANDOLAPRIL;
VALSARTAN;
VASODILATOR AGENT;
ANGIOTENSIN 1 RECEPTOR;
ANGIOTENSIN 2 RECEPTOR;
BLOOD PRESSURE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL FEATURE;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DIABETES MELLITUS;
DRUG DOSE TITRATION;
DRUG EFFICACY;
DRUG MECHANISM;
FOLLOW UP;
HEART FAILURE;
HEART INFARCTION;
HEART LEFT VENTRICLE FAILURE;
HUMAN;
HYPERTENSION;
KIDNEY DISEASE;
KIDNEY FUNCTION;
MONOTHERAPY;
MORBIDITY;
MORTALITY;
PROTEINURIA;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
RENOVASCULAR HYPERTENSION;
REVIEW;
RISK REDUCTION;
STROKE;
DRUG COMBINATION;
DRUG EFFECT;
PATHOPHYSIOLOGY;
PHYSIOLOGY;
RISK FACTOR;
ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS;
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
CARDIOVASCULAR DISEASES;
DRUG THERAPY, COMBINATION;
HUMANS;
KIDNEY DISEASES;
RECEPTOR, ANGIOTENSIN, TYPE 1;
RECEPTOR, ANGIOTENSIN, TYPE 2;
RENIN-ANGIOTENSIN SYSTEM;
RISK FACTORS;
|
|
EID: 41749100193
PISSN: 0741238X
EISSN: None
Source Type: Journal
DOI: 10.1007/BF02877776 Document Type: Review |
|
Times cited : (24)
|
|
References (56)
|
